MMP9 and triple-A syndrome: In in vivo experiments, 800 mg/kg GSP could significantly reduce the incidence of AAA, the dilatation of aorta and elastin degradation in media, and dramatically decrease macrophage infiltration and activation and expression of matrix metalloproteinase (MMP) −2 and MMP-9 in the aorta, compared to the AAA model group.